Climb Bio (CLYM) Investor presentation summary

Mission and strategy

• Focused on developing disease-modifying monoclonal antibody (mAb) therapies for immune-mediated diseases, especially those affecting kidney health.

• Leveraging clinically validated B cell targets and proven mAb modalities for indications with clear endpoints and regulatory pathways.

• Targeting expansive commercial opportunities in diseases with high unmet need, including primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), and IgA nephropathy (IgAN).

• Anticipating a data-rich 2026 with multiple clinical readouts across both lead programs.

• Well-resourced with a cash runway into the second half of 2028.

Clinical pipeline and development

• Budoprutug (anti-CD19 mAb) is in development for pMN, ITP, and SLE, with both IV and SC formulations; Fast Track and Orphan Drug Designation granted for pMN.

• CLYM116 (anti-APRIL mAb) is in development for IgAN, with a differentiated sweeper mechanism for improved activity and less frequent dosing.

• Multiple ongoing and planned trials: Phase 2 for pMN, Phase 1b for ITP and SLE, and Phase 1/2 for IgAN, with initial data readouts expected throughout 2026.

• Budoprutug SC formulation offers potential for at-home administration and broader patient reach.

• CLYM116 Phase 1 data in healthy volunteers and Phase 2 in IgAN patients expected in Q3/Q4 2026.

Key clinical results and differentiation

• Budoprutug demonstrated durable B cell depletion, high serologic and clinical remission rates in pMN, and was well tolerated in Phase 1b.

• In ITP, budoprutug showed durable platelet responses and B cell depletion, including in patients previously treated with rituximab.

• Budoprutug offers potential for broad B cell targeting in SLE, with ongoing global and China studies.

• CLYM116 showed deep and durable IgA suppression and a 2-3x longer half-life than sibeprenlimab in nonhuman primates.

• CLYM116's sweeper mechanism enables efficient APRIL elimination and antibody recycling, supporting less frequent dosing.